

Luigi Fattore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6819212/publications.pdf>

Version: 2024-02-01

32
papers

816
citations

471509

17
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1611
citing authors

#	ARTICLE	IF	CITATIONS
1	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	7.1	99
2	MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 2017, 8, 22262-22278.	1.8	89
3	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 318.	8.6	66
4	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Journal of Translational Medicine, 2013, 11, 180.	4.4	61
5	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death and Differentiation, 2019, 26, 1267-1282.	11.2	47
6	Selective targeting of point-mutated KRAS through artificial microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4203-E4212.	7.1	38
7	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer. Oncotarget, 2013, 4, 1253-1265.	1.8	38
8	Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Cell Death and Disease, 2019, 10, 827.	6.3	35
9	TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung. Cell Cycle, 2013, 12, 1696-1703.	2.6	30
10	microRNA-378a-5p is a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	4.9	30
11	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle, 2012, 11, 1455-1467.	2.6	29
12	CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions. Journal of Cellular Physiology, 2020, 235, 1877-1887.	4.1	29
13	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget, 2015, 6, 24823-24841.	1.8	29
14	MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine and Growth Factor Reviews, 2017, 36, 39-48.	7.2	26
15	Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR). Food and Chemical Toxicology, 2015, 76, 77-79.	3.6	25
16	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers, 2019, 11, 1425.	3.7	22
17	Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes. Human Molecular Genetics, 2013, 22, 1771-1782.	2.9	20
18	The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 645069.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma. <i>Cancers</i> , 2020, 12, 3368.	3.7	15
20	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1930.	4.1	15
21	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
22	Drug tolerance to target therapy in melanoma revealed at single cell level: What next?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188440.	7.4	12
23	c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 320.	4.1	8
24	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 53-68.	3.4	6
25	Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. , 2022, 10, e004239.		6
26	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. <i>Cell Communication and Signaling</i> , 2020, 18, 150.	6.5	4
27	ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	2
28	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	4.4	2
29	Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma. , 2016, , .		2
30	Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts. <i>Journal of Translational Medicine</i> , 2017, 15, .	4.4	1
31	Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition. <i>Journal of Translational Medicine</i> , 2014, 12, O2.	4.4	0
32	Abstract 4230: Targeting lung cancer stem cells through fatty acid metabolism. , 2015, , .		0